Comparison · NCT04979988-9feebb8e
Lorlatinib 2L vs Lorlatinib 3L or Later: Number of Participants for Whom Dates of ALK Test Was Available
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lorlatinib 2L vs Lorlatinib 3L or Later: Number of Participants for Whom Dates of ALK Test Was Available. Trial comparisons, record NCT04979988-9feebb8e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04979988-9feebb8e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.883 | 1 | wilson | |
| Risk in group 2 | 1 | 0.851 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.117 | 0.149 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 1 | 1 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lorlatinib 2L | Participants with ALK+ NSCLC who started treatment with lorlatinib as the second-line therapy from 01-May-2019 to 31-Dec-2020 in real world clinical practice after failure of alectinib treatment as the first line therapy were observed in this retrospective study. | 29 | 29 | OG000 |
| Group 2 | Lorlatinib 3L or Later | Participants with ALK positive NSCLC who started treatment with lorlatinib as the third line (3L) or later line therapy from 01-May- 2019 to 31-Dec-2020 in real world clinical practice after failure of alectinib treatment as the first line therapy were observed in this retrospective study. | 22 | 22 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants for Whom Dates of ALK Test Was Available
- Description
- Number of participants for whom dates of performing ALK test was available was presented in this outcome measure.
- Time frame
- At initiation of alectinib treatment (baseline); retrospective data was retrieved and analyzed during 4 months of this observational study
- Population
FAS comprised of participants with confirmed ALK+ NSCLC who started treatment with lorlatinib as the second-line or later therapy from 01-May-2019 to 31-Dec-2020 and had confirmed treatment with alectinib in the first line setting in a medical record.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
- NCT number
- NCT04979988
- Phases
- Conditions
- ALK-positive Non-small-cell Lung Cancer
- Interventions
- Lortlatinib
- Lead sponsor
- Pfizer
- Results first posted
- 2024-04-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04979988?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04979988-9feebb8e